Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 16 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

10Total
Not Applicable (4)
P 1 (4)
P 2 (2)

Trial Status

Unknown9
Completed3
Recruiting2
Not Yet Recruiting1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT07184047Completed

Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers

NCT03199300Active Not RecruitingPrimary

Investigating Cardiovascular Adverse Events Related to Cancer Treatment

NCT04023110Phase 1Completed

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

NCT04737265Phase 1Completed

Pilot Study of an NTproBNP Guided Strategy of Cardioprotection

NCT07032142Phase 1Not Yet Recruiting

Dose Optimization and Efficacy Assessment of a Fluoropyrimidine Antidote

NCT06274268Not ApplicableRecruiting

Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments

NCT05885048Recruiting

Impact of Gonadotoxic Therapies on Fertility

NCT04999332Phase 2Unknown

Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer

NCT05927636Unknown

Systemic Treatment Related Toxicity Identified With a Smartphone APPlication Measuring Step Count

NCT02856048Phase 2Unknown

Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer

NCT02934971UnknownPrimary

Optimized Multi-modality Machine Learning Approach During Cardio-toxic Chemotherapy to Predict Arising Heart Failure

NCT02848807Not ApplicableUnknownPrimary

Chemotherapy-related Toxicity, Nutritional Status and Quality of Life

NCT02781155Phase 1Unknown

Limiting Chemotherapy Side Effects by Using Moxa

NCT01432301UnknownPrimary

Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination

NCT01892852Not ApplicableUnknown

Acupuncture for Chemotherapy-induced Peripheral Neuropathy

NCT01493011Not ApplicableUnknown

Chemotherapy Combined With Whole-body Hyperthermia to Treat Stage IIIB/IV Non Small Cell Lung Cancer

Showing all 16 trials

Research Network

Activity Timeline